Thursday - May 29, 2025

LOGIN  |  REGISTER
Assertio
Recursion

LifeMD to Participate in Two Investor Conferences in October

September 27, 2023 | Last Trade: US$11.47 0.07 -0.61

NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that management will be participating in two upcoming investor conferences in October.

  • LD Micro Main Event XVI Conference, October 3-5, 2023 at the Luxe Sunset Boulevard Hotel in Los Angeles. Management will deliver a company presentation on Tuesday, October 3rd at 3:30 p.m. Pacific time and will be available for one-on-one meetings. Investors can register to watch the presentation here.
  • Maxim Group 2023 Virtual Tech Conference Series: Exploring All Corners of the Tech Sector, October 10-11, 2023. Management will participate in a virtual fireside chat on Tuesday, October 10th at 3:30 p.m. Eastern Time. Investors can register for the conference here.

About LifeMD, Inc.

LifeMD is a leading provider of virtual primary care. LifeMD offers telemedicine, laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men’s health, women’s health, allergy & asthma, and dermatology. Leveraging a vertically-integrated, proprietary digital care platform, a 50-state affiliated medical group, and a US-based patient care center, LifeMD is elevating healthcare by increasing access to top-notch and affordable care. For more information, please visit LifeMD.com.

Company Contact
LifeMD, Inc.
Marc Benathen, CFO
marc@lifemd.com

Media Contact
press@lifemd.com

C4 Therapeutics

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page